Anti-candidal activity of GBR-14206, a new imidazole derivative: Intravenous administration in lipid emulsion form.:Intravenous Administration in Lipid Emulsion Form
スポンサーリンク
概要
- 論文の詳細を見る
GBR-14206, a new imidazole derivative, has been evaluated against systemic infection with Candida albicans in normal and immunocompromised mice. The therapeutic effect of GBR-14206 (as a lipid emulsion) given intravenously to mice infected systemically with C. albicans was superior to that of miconazole. GBR-14206 also showed a candicidal effect in the blood stream at the therapeutic dose. In addition, GBR-14206 inhibited the hyphal growth (yeast to hyphal transformation) in Eagle's minimum essential medium and methionine synthetic medium at the respective concentrations of 0.20 and 0.05μg/ml, which were approximately 3 to 7 times more active than miconazole.These properties suggested that GBR-14206 may be useful for the therapy of systemic candidiasis in human.
- 日本医真菌学会の論文
日本医真菌学会 | 論文
- (1→3)-β-D-グルカン測定の問題点と進歩
- 両側の肺空洞病変にアスペルギルス感染を合併し抗真菌薬, ミカファンギンとイトラコナゾールの併用療法が有効であった Wegener 肉芽腫症の一例
- Trichophyton tonsurans 臨床分離株に対する各種抗真菌薬の in vitro 抗真菌活性
- 爪白癬の治療について : 日本医真菌学会標準化委員会提案2007
- Candida 属菌種のアゾール系薬感受性試験における現行の日本医真菌学会法, およびその改変法とNCCLS M27-A2法との相関性に関する検討